Impact of retinopathy of prematurity on ocular structures and visual functions
Alistair Fielder,1 Hannah Blencowe,2 Anna O’Connor,3 Clare Gilbert4

ABSTRACT
The preterm baby may develop ophthalmic sequelae which can be due to prematurity per se, due to retinopathy of prematurity (ROP) or due to neurological damage. Focusing on the former two, we discuss how in high-income countries the risk of sight-threatening ROP is largely confined to babies <1000 g birth weight (BW), whereas in low-income or middle-income countries babies exceeding 2500 g BW can be blinded. The effects of prematurity and ROP are presented as regional and global estimates of acute-phase ROP and the consequent mild/moderate and severe visual impairment. We discuss sequelae and how they affect the eye and its shape, strabismus and finally consider their impact on visual functions, including visual acuity, the visual field, colour vision and contrast sensitivity.

INTRODUCTION
Retinopathy of prematurity (ROP) is a well-known complication of preterm birth. It is defined as a vision-threatening disease associated with abnormal retinal vascular development at the boundary of the vascularised and avascular peripheral retina. ROP has a clearly described natural history: the timing of its onset and progression being largely determined by postmenstrual age, which is rather consistent across ethnic groups and settings, with more mature infants having an earlier age at onset and a more contracted course to resolution or progression than more immature babies. In this article, we will frequently refer to mild and severe (acute) ROP with clinical findings described according to the International Classification of ROP revisited (box 1).1 The term ‘severe ROP’ signifies ROP associated with clinically important sequelae, which include Stage 3 ROP, ‘threshold’ and now ‘Type 1 ROP’; the last two mentioned being the previous and current indications for treatment (box 2). All three terms are used in the literature to denote severe disease and while there are milder outliers in lesser degrees of Stage 3 ROP, these three categories include all sight-threatening diseases. Mild disease includes all Stage 1 ROP and Stage 2 ROP and nowadays all ROP not meeting Type 1 criteria. These stages usually resolve spontaneously sometimes after only a fleeting appearance.

The more severe degrees of ROP1 4 can have varying degrees of impact on long-term visual function, including blindness. In order of severity, these are distortion and displacement of the macula, stretching and folding of the retina into a fold and retinal detachment which may be partial or total. Fibrous vitreous membranes can develop just behind the lens reminding us of the old term retrolental fibroplasia. In this situation, the eye is likely to be slightly smaller than normal, leading to disruption of structures at the front of the eye which can be associated with inflammation (uveitis), cataract and glaucoma.5 Finally, eyes with end-stage ROP may shrink (phthisis bulbii).

In this paper, we present and discuss the findings of a recent systematic review6 in which the annual incidence of any degree of ROP was estimated as well as the incidence of visual loss from ROP in high-income, middle-income and low-income countries. However, ROP can have widespread impact on the structure and function of the eye, including refractive errors, and can increase the risk of abnormalities of ocular alignment (strabismus) and these topics are also discussed. It must be remembered that preterm infants are also at risk of other causes of visual loss from optic atrophy, and cerebral visual impairment (CVI) secondary to white matter injury. Some children born preterm have problems with visual perception. These topics are only briefly alluded to in this paper.

WHO IS AFFECTED
Risk factors
Which baby develops ROP, and the visual outcome, is greatly influenced by the standard of neonatal care received. In countries where high-quality neonatal care is available, events such as hyperoxia, hypoxia, hypercarbia, blood transfusions, hyperglycaemia and sepsis can all contribute to the development of ROP; but by far the greatest predictors are indices of immaturity—low gestational age (GA) and low birth weight (BW).7 In countries with high-quality neonatal care, sight-threatening ROP is largely confined to babies with BW <1000 g and is very uncommon in babies >1250 g. In settings where the quality of neonatal care is more variable, the population of babies who develop severe ROP differs, with larger, more mature babies also being affected; indeed, severe ROP is being reported in babies over 34 weeks GA with BWs exceeding 2500 g.8 9 This is largely due to prolonged, injudicious use of supplemental oxygen, frequently not blended or adequately monitored, which predominates over all other risk factors. However, many factors compound and contribute. These include depending on the standard of care—all the aforementioned, suboptimal management of labour, poor nutrition and the absence of pain management.10 11

ROP screening and treatment
The available evidence suggests that >50% babies with BW <1000 g develop some degree of acute ROP.11 A recent systematic review and meta-analysis estimated that in 2010 around 184,700 babies developed any ROP worldwide with 53,500 of
Review

Box 1  Describing acute-phase ROP (abbreviated)

Retinopathy of prematurity (ROP) is described by four major parameters according to the International Classification of ROP first devised in 1984 and revised in 2005.1

Acute ROP develops at the growing tips of the developing retinal blood vessels

1. Severity by stage (1–5)
   - Stages 1 and 2: demarcation line and ridge, respectively.
   - Stage 3: ridge with extraretinal fibrovascular proliferation and carries a significant risk of adverse visual outcome.
   - Stages 4 and 5 represent partial and total retinal detachment, respectively, and result in severe permanent visual impairment.

2. Extent of the disease around the circumference of the globe
   - Recorded in ‘clock hours’.

3. Location of ROP along the antero-posterior meridian
   - Retinal blood vessels grow progressively from Zone 1 to Zone 3, thus the stage of vascularisation is an indicator of maturity. Broadly, zone reflects maturity so ROP in Zone 3 is relatively mild and does not lead to severe disability.

4. Plus disease
   - Engorgement and tortuosity of the retinal blood vessels near the optic disc. Plus is a powerful indicator of ROP activity.

Box 2  ROP treatment indications

Following the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity in 1988,2 the criterion for treatment was ‘Threshold’ retinopathy of prematurity (ROP). This is THE rather than A threshold as the term threshold has a specific meaning in the ROP field. Threshold ROP is defined as the stage at which the risk of blindness if untreated is estimated to be 50%. Between 1988 and 2003, the indication for treatment was

Threshold ROP:
- At least 5 continuous or 8 cumulative clock hours of Stage 3 ROP
- In Zones 1 or II, and in the presence of plus disease.

In 2003, Threshold was superseded by the revised recommendations for treatment proposed by the Early Treatment for Retinopathy of Prematurity (ETROP) Cooperative Group.3 These criteria are referred to as pre threshold, Type I ROP, include threshold as defined above.

ETROP Recommendations:
- Type I ROP
  - Zone I any stage of ROP with plus disease and Stage 3 without plus disease
  - Zone II Stage 2 or 3 with plus disease.

these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.

In a small proportion of babies, ROP does not resolve but progresses to become severe, requiring treatment (box 2). Laser is currently the preferred modality.7 Antivascular endothelial growth factor agents (ranibizumab or bevacizumab), despite a paucity of clinical research evidence, are being increasingly used, either as a primary treatment or as a rescue therapy after laser failure. However, the ocular and systemic safety and long-term efficacy of these agents are not yet known.12 A high proportion of eyes with untreated severe ROP (approximately 60%) and a proportion of treated eyes can develop scarring and distortion of the retina, or retinal detachment, with irreversible vision loss. The role of vitrectomy for the management of these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.

In small proportion of babies, ROP does not resolve but progresses to become severe, requiring treatment (box 2). Laser is currently the preferred modality.7 Antivascular endothelial growth factor agents (ranibizumab or bevacizumab), despite a paucity of clinical research evidence, are being increasingly used, either as a primary treatment or as a rescue therapy after laser failure. However, the ocular and systemic safety and long-term efficacy of these agents are not yet known.12 A high proportion of eyes with untreated severe ROP (approximately 60%) and a proportion of treated eyes can develop scarring and distortion of the retina, or retinal detachment, with irreversible vision loss. The role of vitrectomy for the management of these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.

In small proportion of babies, ROP does not resolve but progresses to become severe, requiring treatment (box 2). Laser is currently the preferred modality.7 Antivascular endothelial growth factor agents (ranibizumab or bevacizumab), despite a paucity of clinical research evidence, are being increasingly used, either as a primary treatment or as a rescue therapy after laser failure. However, the ocular and systemic safety and long-term efficacy of these agents are not yet known.12 A high proportion of eyes with untreated severe ROP (approximately 60%) and a proportion of treated eyes can develop scarring and distortion of the retina, or retinal detachment, with irreversible vision loss. The role of vitrectomy for the management of these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.

In small proportion of babies, ROP does not resolve but progresses to become severe, requiring treatment (box 2). Laser is currently the preferred modality.7 Antivascular endothelial growth factor agents (ranibizumab or bevacizumab), despite a paucity of clinical research evidence, are being increasingly used, either as a primary treatment or as a rescue therapy after laser failure. However, the ocular and systemic safety and long-term efficacy of these agents are not yet known.12 A high proportion of eyes with untreated severe ROP (approximately 60%) and a proportion of treated eyes can develop scarring and distortion of the retina, or retinal detachment, with irreversible vision loss. The role of vitrectomy for the management of these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.

In small proportion of babies, ROP does not resolve but progresses to become severe, requiring treatment (box 2). Laser is currently the preferred modality.7 Antivascular endothelial growth factor agents (ranibizumab or bevacizumab), despite a paucity of clinical research evidence, are being increasingly used, either as a primary treatment or as a rescue therapy after laser failure. However, the ocular and systemic safety and long-term efficacy of these agents are not yet known.12 A high proportion of eyes with untreated severe ROP (approximately 60%) and a proportion of treated eyes can develop scarring and distortion of the retina, or retinal detachment, with irreversible vision loss. The role of vitrectomy for the management of these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.

In small proportion of babies, ROP does not resolve but progresses to become severe, requiring treatment (box 2). Laser is currently the preferred modality.7 Antivascular endothelial growth factor agents (ranibizumab or bevacizumab), despite a paucity of clinical research evidence, are being increasingly used, either as a primary treatment or as a rescue therapy after laser failure. However, the ocular and systemic safety and long-term efficacy of these agents are not yet known.12 A high proportion of eyes with untreated severe ROP (approximately 60%) and a proportion of treated eyes can develop scarring and distortion of the retina, or retinal detachment, with irreversible vision loss. The role of vitrectomy for the management of these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.

In small proportion of babies, ROP does not resolve but progresses to become severe, requiring treatment (box 2). Laser is currently the preferred modality.7 Antivascular endothelial growth factor agents (ranibizumab or bevacizumab), despite a paucity of clinical research evidence, are being increasingly used, either as a primary treatment or as a rescue therapy after laser failure. However, the ocular and systemic safety and long-term efficacy of these agents are not yet known.12 A high proportion of eyes with untreated severe ROP (approximately 60%) and a proportion of treated eyes can develop scarring and distortion of the retina, or retinal detachment, with irreversible vision loss. The role of vitrectomy for the management of these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.

In small proportion of babies, ROP does not resolve but progresses to become severe, requiring treatment (box 2). Laser is currently the preferred modality.7 Antivascular endothelial growth factor agents (ranibizumab or bevacizumab), despite a paucity of clinical research evidence, are being increasingly used, either as a primary treatment or as a rescue therapy after laser failure. However, the ocular and systemic safety and long-term efficacy of these agents are not yet known.12 A high proportion of eyes with untreated severe ROP (approximately 60%) and a proportion of treated eyes can develop scarring and distortion of the retina, or retinal detachment, with irreversible vision loss. The role of vitrectomy for the management of these developing Type I disease (table 1).6 The majority (77%) of these in babies were in low-income and middle-income settings, with 27 000 (15%) being only moderately preterm (born at >32 weeks gestation). These are likely to be underestimates as the study focused on babies receiving neonatal intensive care as data were not available for babies in lower level facilities who may also receive poorly monitored supplemental oxygen.
IMPACT OF ROP ON OCULAR STRUCTURE AND FUNCTION

Very preterm babies are more likely to develop sequelae other than those attributable to ROP compared with more mature preterm babies. The former have gestational periods that might have been shortened by up to 40%, meaning that other aspects of the visual system are also more immature at birth and vulnerable to perturbation. Extremely preterm babies are also likely to develop other comorbidities such as respiratory distress syndrome, sepsis, bronchopulmonary dysplasia and, of particular relevance to the visual system, white matter injury.15

Following the natural or induced regression of acute-phase ROP, a wide range of changes affecting the retina and the retinal vasculature may result.14 How extensive these residuals are depends of the severity of the acute process. Mild sequelae have not attracted great interest until now, partly because they are difficult to visualise in detail in the older baby and young child, but also because they have less impact on visual function. The following retinal sequelae of severe acute ROP do not usually have an impact on visual function: persistence of retinal vessel tortuosity, peripheral pigmentary retinal changes and vascular anomalies. With increasing severity, vision is affected: the retina and its vessels are ‘dragged’ towards the site of previous acute ROP (usually temporally) as shown by straightening and narrowing of the angle between the major vessels arising from the optic disc (Figure 1). Finally, the macula is distorted, the retina can be detached and fibrous membranes develop in the vitreous as mentioned in the Introduction section.

Regression of severe acute-phase ROP, induced or not by treatment, is not necessarily the end of the story as there is an increased risk of retinal detachment later in life for two reasons: first, the effect of being born preterm and second, as a consequence of ROP.

Early exteriorisation due to preterm birth shortens the intrauterine period and removes the fetus from a protective environment ideally suited to promote growth and provides the optimal level of stimulation. Unsurprisingly, the visual system of the preterm baby can be affected by removal from this milieu as well as by exposure to a very different biological and physical environment. Fledelius demonstrated over 30 years ago that the eyes of children born prematurely but who did not have ROP did not grow normally.18 He showed that structures at the front of the eye, namely the cornea and lens, both of which play a vital role in focusing light onto the retina, were different:

**Table 1** Regional and global estimates of the annual incidence of retinopathy of prematurity (ROP), by severity, the number treated and the annual incidence of visual loss, by severity (from Blencowe)6

<table>
<thead>
<tr>
<th></th>
<th>High income</th>
<th>Middle income</th>
<th>Low income</th>
<th>Total*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number with any ROP</td>
<td>41 400</td>
<td>139 000</td>
<td>4300</td>
<td>184 700</td>
</tr>
<tr>
<td>% of global total</td>
<td>22%</td>
<td>75%</td>
<td>2%</td>
<td>100%</td>
</tr>
<tr>
<td>Number with severe ROP</td>
<td>8700</td>
<td>43 400</td>
<td>1400</td>
<td>53 500</td>
</tr>
<tr>
<td>Phenotype of babies with severe ROP</td>
<td>Most &lt;1250 g; all &lt;1500 g</td>
<td>Wide heterogeneity with babies affected up to &lt;~2500 g and &lt;~34 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number treated for severe ROP</td>
<td>6700</td>
<td>15 700</td>
<td>300</td>
<td>22 700</td>
</tr>
<tr>
<td>% of cases of severe ROP treated</td>
<td>79%</td>
<td>38%</td>
<td>21%</td>
<td></td>
</tr>
<tr>
<td>Number with mild/moderate visual impairment from ROP</td>
<td>2900</td>
<td>9200</td>
<td>200</td>
<td>12 300</td>
</tr>
<tr>
<td>Number with severe visual impairment or blind from ROP</td>
<td>2600</td>
<td>16 900</td>
<td>600</td>
<td>20 000</td>
</tr>
<tr>
<td>Total with visual loss</td>
<td>5400</td>
<td>26 100</td>
<td>800</td>
<td>32 300</td>
</tr>
<tr>
<td>% of total burden of ROP-associated visual loss</td>
<td>17%</td>
<td>81%</td>
<td>2%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Source: data based on reanalysis of Blencowe et al by WHO income groupings. Numbers may not sum due to rounding.


**Figure 1** Straightening of the retinal vessels arising from the optic disc and narrowing of the angle between the major vessels. Mild dragging of the vessels to the left of the image, extending across the macula towards the temporal retinal periphery.
corneas of children born preterm are more curved, and the lens is thicker, both of which increase the focusing power of the eye, leading to short-sightedness (myopia). This myopia, which is not due to ROP, is of low degree and is referred to as ‘myopia of prematurity’.18–21 Studies have shown that all individuals born preterm are more prone than their full-term counterparts to all refractive errors—astigmatism (irregular curvature of the cornea which distorts vision), hypermetropia (long-sightedness) and anisometropia (different refractive state between the two eyes).19 20

While mild ROP does not contribute additionally to refractive state, following severe acute ROP refractive development is very different, as all of the aforementioned refractive errors occur, but to a greater degree19 21 22 and high myopia (>5 dioptres) only occurs following severe ROP. The prevalence of refractive errors varies across studies, as shown in Table 2, being highest in the extremely low BW group (ie, BW <1000 g) and following treatment for severe ROP. Myopia attracts the most attention23 as high degrees are not rare and even a small amount of myopia affects distance visual acuity which requires correction. In contrast, the impact of hypermetropia on visual performance is not linear and its correction is not clearly defined, although there is no doubt that higher degrees do need to be corrected.24

Long debated, it appears that myopia following severe ROP is related to the disease process itself and is not a complication of ROP treatment by cryotherapy or laser. Myopia associated with severe ROP progresses during the first 6–9 months and to a lesser extent thereafter, becoming relatively stable by around 3 years of age. This is quite different from the mild myopia associated with prematurity which has a later onset and progresses in severity into the teens. It is possible that myopia is less following bevacizumab treatment compared with laser or cryotherapy, a potentially important finding which needs further study.

To summarise, refractive development is perturbed by preterm birth per se and expreterm children have an increased prevalence of all refractive errors, especially low myopia. Mild ROP does not contribute to the refractive state, over and above that which is attributable to preterm birth. Following severe ROP, there is an increase in all refractive errors, including myopia, and frequently high myopia.

### STRABISMUS

One of the visible signs of a disturbance in the normal process of visual development is the presence of strabismus (misalignment of the eyes) which can be due to loss of vision in one or both eyes, cranial nerve palsies and/or disorders of the higher visual pathways. Prevalence ranges from 16% to 22% in preterm children,19 21 28 29 which is substantially higher than among children born at term (1–3%). All studies report that strabismus is more prevalent in preterm children, but the findings in relation to ROP differ, one study reporting increase by ROP stage, not confirmed in another study. Recently, it was reported that 60% of children with Type I ROP had strabismus.40 Some of the differences may be attributable to classification by clinical characteristics, not aetiology. Given the higher rates of neurological deficits in children with ROP and that neurological deficits due to white matter injury are associated with a high incidence of strabismus,28 31 it is impossible to determine the direct impact of ROP alone. Strabismus per se can lead to loss of visual function from strabismic amblyopia and thus needs to be detected so that the child can be referred for treatment.

### VISUAL FUNCTIONS

Following preterm birth, there are three key factors that influence visual outcome, the presence of ROP or neurological comorbidities and preterm birth itself.

Table 1 clearly demonstrates the high rates of visual impairment following ROP and while the rates are lower with a higher rate of treated cases, treatment infrequently results in normal vision with 35%, 49% and 75% achieving 6/12 or better, 6/18 or better and 6/60 or better32—data not fully excluding CVI. That significant retinal damage resulting from severe ROP is clearly linked to long-term visual impairment, however, milder forms of ROP may also impact on visual outcome, but epidemiological studies have differed in their findings in this respect. This may be because mild ROP is transient and may therefore not be identified, falsely biasing conclusions. While it is not clear whether mild ROP affects vision, as preterm birth itself confers an additional risk for impaired visual function, not identifying all cases may be biasing the conclusions.

### Table 2 Refractive state following preterm birth with and without retinopathy of prematurity (ROP)

<table>
<thead>
<tr>
<th>Study</th>
<th>BW/GA</th>
<th>ROP</th>
<th>Age</th>
<th>Refractive errors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPRESS19</td>
<td>&lt;27 weeks</td>
<td>73.7% (20.4% treated)</td>
<td>30 months</td>
<td>25.6%—all</td>
</tr>
<tr>
<td></td>
<td>&lt;1251 g</td>
<td>All reached threshold (82.5% bilateral)</td>
<td>3.5 years</td>
<td>Moderate myopia (≥2 D to &lt;6 D):</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treated eyes 20.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Untreated eyes 15.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>High myopia (≥6 D):</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treated eyes 37.7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Untreated eyes 27.2%</td>
</tr>
<tr>
<td>CRYO-ROP Study26</td>
<td>&lt;1251 g</td>
<td>High-risk prethreshold</td>
<td>6 years</td>
<td>Astigmatism ≥52% in all treated eyes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>High astigmatism ≥23% in all treated eyes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Myopia ≥65% in all treated eyes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>High myopia≥35% in all treated eyes</td>
</tr>
<tr>
<td>ETROP27</td>
<td>&lt;1501 g</td>
<td>39%</td>
<td>10 years</td>
<td>Moderate myopia 3.8%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Moderate hypermetropia 4.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Astigmatism 21%</td>
</tr>
<tr>
<td>ETROP23</td>
<td>&lt;1701 g</td>
<td>50%</td>
<td>10–12 years</td>
<td>Mild myopia 15.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Moderate myopia 3.8%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Moderate hypermetropia 6.6%</td>
</tr>
</tbody>
</table>

Refractive errors are defined (unless otherwise stated) as mild myopia <3.0 dioptre sphere, moderate ≥3 dioptre sphere, high myopia >5.0 dioptre sphere, moderate hypermetropia ≥3.0 dioptre sphere, astigmatism ≥1.00 dioptres and high astigmatism ≥2.00 dioptres.

BW, birth weight; D, dioptre; GA, gestational age.
Comorbidities such as neurological disorders due to white matter injury can have a significant impact on a child’s visual abilities. The resultant CVI is now the most common cause of visual impairment in children in the developed world. Differentiating the effects on vision of CVI and ROP can be difficult except when the retina is obviously disorganised. CVI encompasses a wide range of effects from blindness through to visual neglect and simultanagnosia (inability to process a crowded scene). The latter may not be detected by routine clinical assessment such as visual acuity measurement, requiring specific questions to elicit difficulties in visual perception.

Of course, real life vision depends on more than visual acuity, and impaired visual function can occur in the presence of normal visual acuity. Other functions to consider include the visual field, colour vision and contrast sensitivity.

**Visual acuity**

It has long been known that children who were born preterm, but did not have ROP, may have reduced visual acuity compared with children born at full term. These deficits are subtle with acuity levels usually lying at the lower border of the normal range. The basis of these acuity deficits has hitherto been unknown, but recent advances in optical coherent tomography show that children born preterm can have subtle changes in the detailed anatomy of the central retina. However, these structural abnormalities do not correlate very well with function, which suggests that other processes are also involved.

**The visual field**

In the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity, it was reported that at the age of 10 years the visual field was constricted to a similar extent (ie, by 5° to 10°) whether or not the ROP had been treated by peripheral retinal ablation; this was subsequently confirmed by Larsson and coworkers. Laser ablative treatment at the earlier stage of Type I prethreshold not only did not cause further constriction as feared, but counterintuitively resulted in slight preservation of the field compared with eyes treated at threshold. The level of visual field constriction attributable to ROP does not have a major functional impact and driving is not precluded.

**Colour vision and contrast sensitivity**

Subtle colour vision deficits have been described in association with preterm birth but are ROP independent. Contrast sensitivity is an important visual function and may be adversely affected by preterm birth, neurological abnormalities and severe ROP. While the clinical measures of visual function are made in isolation, they frequently coexist. The cumulative impact on functional ability is unknown, in particular in a group of children that may have other physical disabilities, and while normal visual acuity may not be a realistic goal, all treatments aim to maximise visual function.

**CONCLUSION**

We have described the sequelae of ROP but differentiating the effects of preterm birth, ROP and neurological damage can be difficult and sometimes impossible. In general, being born early does affect the visual system and its functions, albeit to a relatively mild degree, and mild ROP does not (with one or two exceptions) contribute additionally to these deficits. There have been major advances in ROP treatment over the past three decades; however, severe ROP, even if treated, still results in a degree of visual disability, fortunately of lesser severity than previously. Looking forward, the prevention of ROP through high-quality neonatal care, including the safe use of oxygen, is critical to improve visual outcomes in preterm infants worldwide.

**Competing interests** None.

**Provenance and peer review** Commissioned; externally peer reviewed.

**REFERENCES**